Recent news

Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics in patients with sepsis.

December 12, 2022

Hence, this important study reveals how microbial exploitation of phagocytic receptors is linked to triggering of sepsis and the immune cell mediated reduction in neutrophil life span. The explored pathway creates a novel therapeutic opportunity for NucleoCapture, which would eliminate circulating chromatin and aid with immune dysfunction without compromising the defensive function of neutrophils.

September 30, 2021

Santersus AG announces the successful completion of their first in human clinical trials relating to Sepsis and COVID-19.

This important publication reveals the profound impact of cell-free DNA clearance and its involvement in the survival of patients who suffer from severe SARS-CoV-2 infection. This obviously presents a novel therapeutic opportunity for our technology, NucleoCapture, which allows for selective removal of NETs from blood without compromising the defensive function of neutrophils.

January 11, 2021

First patients is enrolled to First In-Human Clinical Trial of NucleoCapture®

December 2, 2021

Ethics Committees of two major clinics approved NucleoCapture to proceed with a clinical trial in Sepsic Patients

November 26, 2021

Santersus’ Shareholders Elect New Board Members

September 22, 2021

Santersus AG Confirms Attendance at BioTech Gate

September 1, 2021

Santersus Raises CHF 750 thousand in Family & Friends Round

1 2 3 >